GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relypsa Inc (NAS:RLYP) » Definitions » EBIT

Relypsa (Relypsa) EBIT : $-229.19 Mil (TTM As of Jun. 2016)


View and export this data going back to 2013. Start your Free Trial

What is Relypsa EBIT?

Relypsa's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2016 was $-65.83 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2016 was $-229.19 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Relypsa's annualized ROC % for the quarter that ended in Jun. 2016 was -995.72%. Relypsa's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2016 was -2,583.84%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Relypsa's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2016 was -15.96%.


Relypsa EBIT Historical Data

The historical data trend for Relypsa's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relypsa EBIT Chart

Relypsa Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15
EBIT
-25.53 -43.34 -70.91 -77.99 -176.97

Relypsa Quarterly Data
Dec11 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -38.78 -51.03 -57.98 -54.35 -65.83

Competitive Comparison of Relypsa's EBIT

For the Biotechnology subindustry, Relypsa's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Relypsa's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relypsa's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Relypsa's EV-to-EBIT falls into.



Relypsa EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-229.19 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Relypsa  (NAS:RLYP) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Relypsa's annualized ROC % for the quarter that ended in Jun. 2016 is calculated as:

ROC % (Q: Jun. 2016 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2016 ) + Invested Capital (Q: Jun. 2016 ))/ count )
=-263.332 * ( 1 - 0% )/( (28.637 + 24.256)/ 2 )
=-263.332/26.4465
=-995.72 %

where

Invested Capital(Q: Mar. 2016 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=261.384 - 48.076 - ( 205.266 - max(0, 54.525 - 239.196+205.266))
=28.637

Invested Capital(Q: Jun. 2016 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=321.577 - 41.504 - ( 257.726 - max(0, 42.656 - 298.473+257.726))
=24.256

Note: The Operating Income data used here is four times the quarterly (Jun. 2016) data.

2. Joel Greenblatt's definition of Return on Capital:

Relypsa's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2016 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2016 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2016  Q: Jun. 2016
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-263.332/( ( (10.089 + max(-19.843, 0)) + (10.294 + max(-2.868, 0)) )/ 2 )
=-263.332/( ( 10.089 + 10.294 )/ 2 )
=-263.332/10.1915
=-2,583.84 %

where Working Capital is:

Working Capital(Q: Mar. 2016 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.513 + 24.873 + 7.726) - (48.076 + 4.879 + 0)
=-19.843

Working Capital(Q: Jun. 2016 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.338 + 31.881 + 6.569) - (41.504 + 1.152 + 0)
=-2.868

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2016) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Relypsa's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2016 )
=-229.19/1435.790
=-15.96 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Relypsa EBIT Related Terms

Thank you for viewing the detailed overview of Relypsa's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Relypsa (Relypsa) Business Description

Traded in Other Exchanges
N/A
Address
Relypsa Inc is a biopharmaceutical company engaged in the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases.
Executives
Ronald A. Krasnow officer: See Remarks C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Kristine M Ball officer: Chief Financial Officer & SVP C/O RELYPSA, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Mcgirr David W J director 33 PHEASANT LANE, GREENWICH CT 06830
Paul J Hastings director 61 HARTFORD STREET, SAN FRANCISCO CA 94114
John A Orwin director, officer: President & CEO C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Kenneth J. Hillan director C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Wilhelm Stahl officer: SVP, Chief Technology Officer C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
J. Scott Garland officer: SVP & Chief Commercial Officer 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
John P. Butler director C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Helen Torley director C/O ONYX PHARMACEUTICALS, INC., 249 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
James D Dondero 10 percent owner 300 CRESCENT COURT, SUITE 700, DALLAS TX 75201
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Samuel D Isaly 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Iv Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022

Relypsa (Relypsa) Headlines

From GuruFocus

Insiders Buy Stock in Wynn Resorts, Bank of New York Mellon

By Tiziano Frateschi Tiziano Frateschi 10-26-2015